Predictive Serum Lipid Biomarkers for Preeclampsia ID: 2015-056

An innovative diagnostic approach using serum lipid biomarkers to predict preeclampsia as early as 12 to 14 weeks into pregnancy.

Technology Overview

This invention, developed at Brigham Young University, introduces a clinical diagnostic and predictive test for preeclampsia using serum lipid biomarkers. It stands out for its early detection capabilities, potentially identifying the condition in the first trimester. This method surpasses previous protein-based biomarkers in sensitivity and practicality, offering a significant leap in prenatal care and maternal health.

Key Advantages

• Early detection of preeclampsia, as soon as 12 to 14 weeks into pregnancy
• High predictive accuracy, identifying over 90% of cases
• Improves upon the sensitivity issues of previous biomarker-based tests
• Can be easily integrated into clinical practice or utilized through reference laboratories

Problems Addressed

• Lack of early and accurate diagnostic tests for preeclampsia
• Insensitivity and impracticality of previous serum protein biomarkers
• Delayed intervention and management of preeclampsia due to late diagnosis

Market Applications

• Clinical diagnostics for early detection of preeclampsia in pregnant women
• Use in prenatal care programs to monitor at-risk pregnancies
• Reference laboratories offering specialized testing services
• Integration into existing maternal healthcare protocols to improve outcomes

Additional Information

Technology ID: 2015-056
Sell Sheet: Download the Sell Sheet here
Market Analysis: Contact us for a more in-depth market report
Date Published: 28 March, 2025